OPKO Health : Immediate Report

Form 144 Filer Information		UNITED STATES
		SECURITIES AND EXCHANGE COMMISSION
		Washington, D.C. 20549
FORM 144		Form 144
		NOTICE OF PROPOSED SALE OF SECURITIES
	PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
144: Filer Information
Filer CIK	0000944809
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address
144: Issuer Information
Name of Issuer	GeneDx Holdings Corp.
SEC File Number	001-39482
Address of Issuer	333 LUDLOW STREET
		NORTH TOWER, 6TH FLOOR
		STAMFORD
		CONNECTICUT
		06902
Phone	888-729-1206
Name of Person for Whose Account the	OPKO HEALTH, INC.
Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer 10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Common Stock
Name and Address of the Broker	Charles Schwab & Co.
	3000 Schwab Way
	Westlake
	TX
	76262
Number of Shares or Other Units To Be	261417
Sold
Aggregate Market Value	6964148.00
Number of Shares or Other Units	26141701
Outstanding
Approximate Date of Sale	06/28/2024
Name the Securities Exchange	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or

any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

	Title of the Class		Class A Common Stock
	Date you Acquired	04/29/2022
	Nature of Acquisition Transaction		Compensation for Sale of GeneDX to Sema 4
	Name of Person from Whom Acquired		Issuer
	Is this a Gift?			Date Donor Acquired
	Amount of Securities Acquired	261417
	Date of Payment	04/29/2022
	Nature of Payment		N/A

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice	06/27/2024
ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature	Adam Logal

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)